Onderzoeker
Hendrik Everaert
- Trefwoorden:Geneeskunde
- Disciplines:Nucleaire beeldvorming
Affiliaties
- Medische Beeldvorming (Onderzoeksgroep)
Lid
Vanaf1 jan 2011 → Heden - nucleaire geneeskunde (Departement)
Lid
Vanaf1 jan 2008 → Heden - Ondersteunende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 28 feb 2023 - Ondersteunende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → 20 okt 2022 - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 mrt 2010 → 31 dec 2013 - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 okt 2002 → 30 sep 2010
Publicaties
1 - 10 van 22
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Auteurs: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, K Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pagina's: 1378-1384 - Preoperative Radiotherapy with a Simultaneous Integrated Boost Compared to Chemoradiotherapy for cT3-4 Rectal Cancer(2023)
Auteurs: Benedikt Engels, Antonino De Paoli, Elena Delmastro, Fernando Munoz, Stefano Vagge, Darius Norkus, Hendrik Everaert, Gianna Tabaro, Elisabetta Gariboldi, Umberto Ricardi, et al.
- Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series(2023)
Auteurs: Jens Tijtgat, Evan Maarten Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, A Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, et al.
- The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression(2021)
Auteurs: Karolien Vekens, Hendrik Everaert, Bart Neyns, Bart Ilsen, Lore Decoster
Pagina's: 432-440 - Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients(2021)
Auteurs: Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D Windhorst, Frank Van Der Aa, N Harry Hendrikse, et al.
Pagina's: 1097-1105 - Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio(2021)
Auteurs: Vincent Vinh-Hung, Hendrik Everaert, Olena Gorobets, Hilde Van Parijs, Guy Verfaillie, Marian Vanhoeij, Guy Storme, Christel Fontaine, Jan Lamote, Justine Perrin, et al.
Pagina's: 956-968 - A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
- Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome(2021)
Auteurs: Sim Vermeulen, Gil Awada, M Keyaerts, Bart Neyns, Hendrik Everaert
Pagina's: 1630-1640 - A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Auteurs: Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly A Schats, Pieter-Jan van Dam, et al.
Pagina's: 1-18 - Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)(2020)
Auteurs: Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, et al.
Pagina's: 1-12